Anhedonia

Xenon Pharmaceuticals Presents Data from Phase 2 X-NOVA Clinical Trial of Azetukalner in Major Depressive Disorder at the American Society of Clinical Psychopharmacology 2024 Annual Meeting

Retrieved on: 
Dienstag, Mai 28, 2024
Xenon, Patient, Novel, Weight gain, BAI, MDD, Major depressive disorder, Depression, Anxiety, Political moderate, Incidence, DSM-IV codes, ASCP, Society, Physician, Clinical Global Impression, Anhedonia, Annual general meeting, Surveying

VANCOUVER, British Columbia, May 28, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, announced data presentations highlighting azetukalner (XEN1101) clinical data in major depressive disorder (MDD) at the American Society of Clinical Psychopharmacology (ASCP) 2024 Annual Meeting in Miami, FL.

Key Points: 
  • VANCOUVER, British Columbia, May 28, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, announced data presentations highlighting azetukalner (XEN1101) clinical data in major depressive disorder (MDD) at the American Society of Clinical Psychopharmacology (ASCP) 2024 Annual Meeting in Miami, FL.
  • Mr. Ian Mortimer, Xenon’s President and Chief Executive Officer, stated, “We are pleased to present these data from our Phase 2 proof-of-concept X-NOVA study of azetukalner in MDD at the ASCP meeting.
  • The primary endpoint of the study was a change in the Montgomery-Åsberg Depression Rating Scale, or MADRS, at week 6.
  • There were no statistically significant differences in change from baseline BAI total scores to week 6 between placebo and azetukalner groups.

Alto Neuroscience Reports First Quarter 2024 Financial Results and Recent Business Highlights

Retrieved on: 
Dienstag, Mai 14, 2024
Mental Health, Health, FDA, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, CIAS, PET, Partnership, Patient, PDE4, Human, EEG, MDD, Central nervous system disease, Depression, Overalls, Safety, NMDA, Dopamine, Neuroscience, CNS, DSM-IV codes, Brain, Society, Psychopharmacology, Research, Schizophrenia, Anhedonia, Cognition, Histamine, Pharmaceutical industry

Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today reported financial results for the first quarter ended March 31, 2024, and highlighted recent corporate progress.

Key Points: 
  • Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today reported financial results for the first quarter ended March 31, 2024, and highlighted recent corporate progress.
  • Alto is currently evaluating ALTO-100 in a 266-patient Phase 2b study in MDD patients characterized by a memory-based cognitive biomarker.
  • Enrollment is ongoing and the Company expects to report topline data in the second half of 2024.
  • Net Loss: The Company incurred a net loss of $13.4 million for the quarter ended March 31, 2024, as compared to $7.3 million for the quarter ended March 31, 2023.

Xenon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

Retrieved on: 
Donnerstag, Mai 9, 2024
FDA, American Academy, Neurocrine Biosciences, Internet, International, WHO, SCN8A, USAN, Nav1.7, World Health Organization, Safety, NDA, PIN, Food, ASCP, Research, Anhedonia, Depression, Webcast, Information technology, IND, INN, OLE, DSM-IV codes, Patient, Society, Epilepsy, Drug discovery, FOS, SCN1A, Ageing, Pharmaceutical industry

VANCOUVER, British Columbia, May 09, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, today reported financial results for the first quarter ended March 31, 2024 and provided a corporate update.

Key Points: 
  • Successful “end-of-Phase 2” interactions with FDA in MDD; Phase 3 program on track to initiate in the second half of the year
    VANCOUVER, British Columbia, May 09, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, today reported financial results for the first quarter ended March 31, 2024 and provided a corporate update.
  • Other income was $11.5 million for the first quarter of 2024, compared to $7.6 million for the same period in 2023.
  • Net loss was $47.9 million for the first quarter of 2024, compared to $41.7 million for the same period in 2023.
  • Xenon will host a conference call and webcast today at 4:30 pm Eastern Time (1:30 pm Pacific Time) to discuss its first quarter results.

Alto Neuroscience Announces Initiation of Phase 2 Study of ALTO-203 in Patients with Major Depressive Disorder

Retrieved on: 
Mittwoch, April 3, 2024
Mental Health, Health, Neurology, Clinical Trials, Pharmaceutical, Biotechnology, Alertness, Depression, EEG, Motivation, ClinicalTrials.gov, MDD, Patient, Neuroscience, Anhedonia, H3, Pleasure, Alto, Cognition, Safety, Pharmacokinetics, Pharmaceutical industry

Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced the initiation of its Phase 2 double-blind, single- and multiple-dose study to determine the pharmacodynamic effects of ALTO-203 in MDD patients as well as assess its safety, tolerability, and pharmacokinetics.

Key Points: 
  • Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced the initiation of its Phase 2 double-blind, single- and multiple-dose study to determine the pharmacodynamic effects of ALTO-203 in MDD patients as well as assess its safety, tolerability, and pharmacokinetics.
  • The present study will evaluate these effects in patients with MDD to determine the potential of ALTO-203 as an antidepressant.
  • “In a Phase 1 study, ALTO-203 demonstrated an acute increase in positive emotion relative to placebo and across several dosage levels.
  • This Phase 2 study consists of two sequential double-blind, placebo-controlled treatment periods and examines two doses of ALTO-203 and placebo given as monotherapy in patients with MDD.

Alto Neuroscience Reports Full Year 2023 Financial Results and Recent Business Highlights

Retrieved on: 
Donnerstag, März 21, 2024
Biotechnology, Mental Health, Health, Pharmaceutical, Clinical Trials, Modafinil, Research, Depression, EEG, DSM-IV codes, Histamine, Brain, Regenerative medicine, CFO, NMDA, MDD, Partnership, Patient, CNS, CIAS, Neuroscience, CIRM, Anhedonia, IPO, PDE4, Overalls, IND, Biogen, Cognition, Johnson & Johnson, Central nervous system disease, Pharmaceutical industry

Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today reported financial results for the full year ended December 31, 2023, and highlighted recent corporate progress.

Key Points: 
  • Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today reported financial results for the full year ended December 31, 2023, and highlighted recent corporate progress.
  • In January 2023, Alto reported positive results from a Phase 2a study in which patients with MDD and a cognitive biomarker signature were identified as more responsive to ALTO-100.
  • Alto is currently evaluating ALTO-100 in a 266-patient Phase 2b study in MDD patients characterized by the cognitive biomarker.
  • The increase was primarily attributable to costs associated with the Phase 2a clinical studies for ALTO-100 and ALTO-300, which were completed in 2023.

Cybin Receives FDA Breakthrough Therapy Designation for its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder

Retrieved on: 
Mittwoch, März 13, 2024
Alternative Medicine, Mental Health, Health, FDA, Clinical Trials, Pharmaceutical, Biotechnology, JAMA, Depression, Disability, Conference, BTD, Breakthrough therapy, Massachusetts General Hospital, Inc., Psychiatry, Clinical, Grammatical mood, Appetite, MDD, Data analysis, Patient, Knowledge, Disease, Causality, Sleep, Anhedonia, DNB, DSM-IV codes, MBBS, Suicidal ideation, Behavior, Cognition, Event, Hospital, Drug development, Safety, Injury, Multimedia, Plasma protein binding, Sadness, Lancet, BMJ, Pharmaceutical industry

If approved by the FDA, CYB003 would be the first known adjunctive psychedelic-based therapeutic for the treatment of MDD.

Key Points: 
  • If approved by the FDA, CYB003 would be the first known adjunctive psychedelic-based therapeutic for the treatment of MDD.
  • The designation of CYB003 as a breakthrough therapy acknowledges the significant unmet medical need for more effective treatments of MDD and supports CYB003’s potential for significant improvements over existing therapies.
  • With the robust durability data from our Phase 2 study in hand, we are ready to move forward expeditiously.
  • (2022) Response to acute monotherapy for major depressive disorder in randomized, placebo-controlled trials submitted to the US Food and Drug Administration: individual participant data analysis.

Mindpath Health releases Daddy Issues: Understanding Attachment Trauma

Retrieved on: 
Mittwoch, Februar 21, 2024
DSM, Incidence, Anxiety, Woman, Caregiver, Mental health, Emotion, Love Is Blind, Emotional dysregulation, Friends, Impulsivity, Love, Parent, Life, Risk, Perception, Dysphoria, Fear, Anhedonia, Family, Chronic pain, Hypervigilance, Child, ADHD, Trauma, DSM-IV codes, Doctor of Psychology, Personality disorder, Depression, Nursing

A psychological name for daddy issues: attachment trauma

Key Points: 
  • A psychological name for daddy issues: attachment trauma
    Clearly, 'daddy issues' is not a clinical term, and you won't find it in the DSM.
  • At its core, 'daddy issues' is a label for something very clinical: attachment trauma.
  • Like many forms of trauma, attachment trauma can have real effects on your mental health .
  • Attachment trauma, or the effects of inconsistent or abusive parenting, shows up in several different insecure attachment styles developed by psychologist John Bowlby .

ANeuroTech publishes Phase IIIa data for ANT-01, an adjunctive anti-depression drug, in Personalized Medicine in Psychiatry

Retrieved on: 
Mittwoch, Januar 31, 2024
Com, Psychosis, Dopamine, Patient, Serotonin, Depression, MDD, Mental health, Phase, Anhedonia, Citalopram, Patent, Prodrug, Pleasure, Pipamperone, Pharmaceutical industry

ANeuroTech publishes Phase IIIa data for ANT-01, an adjunctive anti-depression drug, in Personalized Medicine in Psychiatry

Key Points: 
  • ANeuroTech publishes Phase IIIa data for ANT-01, an adjunctive anti-depression drug, in Personalized Medicine in Psychiatry
    Alken, Belgium – 31 January 2024: ANeuroTech, a leader in the development of innovative mental health treatments with minimal or no side effects, today announced the publication of Phase IIIa data for ANT-01, its adjunctive anti-depression drug, in the journal of Personalized Medicine in Psychiatry.
  • The Company also filed a Composition of Matter (CoM) patent for the long-acting effects of ANT-01.
  • The paper was co-authored by Erik Buntinx, Lars Bastiaanse, Alan S Schatzberg, Charles B Nemeroff and Philip D Harvey.
  • At ANeuroTech, we are working to bring effective treatments, with minimal or no side-effects, to patients who suffer with depression.

Pharmactive's Saffron Extract improves Resilience to Occasional Stress

Retrieved on: 
Mittwoch, Januar 24, 2024
DSM-IV codes, Hypothalamus, Arginine, Iterative method, Pituitary gland, Research, Overalls, Manager, Food, Health, Brain-derived neurotrophic factor, HPA, Hormone, Survival, Communication, History, Nutrient, Anxiety, Pandemic, Human, Gland, Doctor of Philosophy, Rat, Anhedonia, ACTH, Adrenocorticotropic hormone, CRF, Brain, Motivation, Glucocorticoid, BDNF, Depression, Growth

MADRID, Jan. 24, 2024 /PRNewswire/ -- A new in vitro study sheds light to the stress relief effect of saffron (Crocus sativus L). The research highlights the ability of affron®, a standardized extract of saffron developed by Pharmactive Biotech Products to enhance resilience to occasional stress.

Key Points: 
  • The research highlights the ability of affron®, a standardized extract of saffron developed by Pharmactive Biotech Products to enhance resilience to occasional stress.
  • Results demonstrated significant improvements following repeated oral administration of the extract in stress model animal subjects.
  • The HPA axis is a vital brain signaling system involved in orchestrating responses to stress.
  • We are realizing these extend beyond influencing serotonin expression but actually demonstrates a potential to boost resilience to occasional stress and prevent its detrimental impact on overall mental and physical health."

Xenon Pharmaceuticals Announces Topline Results from Phase 2 Proof-of-Concept X-NOVA Clinical Trial of XEN1101 in Major Depressive Disorder (MDD)

Retrieved on: 
Montag, November 27, 2023
Xenon, Șaeș, Physician, Anhedonia, Depression, Epilepsy, American Epilepsy Society, DSM-IV codes, Incidence, SAE, Seizure, Clinical Global Impression, Neurology, Weight gain, MDD, Patient, Safety, Pharmaceutical industry

The primary endpoint of the study was a change in the Montgomery-Åsberg Depression Rating Scale, or MADRS, at week 6.

Key Points: 
  • The primary endpoint of the study was a change in the Montgomery-Åsberg Depression Rating Scale, or MADRS, at week 6.
  • The mean reduction was 13.90 in the placebo group, 15.61 in the XEN1101 10 mg group and 16.94 in the XEN1101 20 mg group.
  • A clear dose response and a clinically meaningful, but not statistically significant, 3.04 difference between placebo and the XEN1101 20 mg group (p=0.135) was observed.
  • We are excited to share the data generated in X-NOVA with epileptologists and neurologists at the upcoming American Epilepsy Society meeting in December.”